FDA Approves Moderna mFLUVISA: First mRNA Flu Vaccine Clears PDUFA

The FDA approved Moderna’s (MRNA) mFLUVISA on August 5, making it the first mRNA-based seasonal influenza vaccine licensed in the United States. The approval, which arrived on the PDUFA deadline, covers adults 50 to 64 under standard approval and adults 65 and older under accelerated approval. Moderna shares closed at $56.26 on August 5, roughly flat on a day when the broader market had already priced in the decision following the 9-0 advisory committee vote in June.

The approval validates a platform searching for a second commercial product beyond Spikevax. mFLUVISA’s Phase 3 data showed a 26.6% relative vaccine efficacy advantage over standard-dose flu vaccines (95% CI, 16.7% to 35.4%), meeting prespecified criteria for both noninferiority and superiority. The trial enrolled roughly 73,000 participants across multiple hemispheres, making it one of the largest influenza vaccine efficacy studies ever conducted. The VRBPAC had voted unanimously in favor on June 18.

As an mRNA vaccine, mFLUVISA offers faster strain matching than egg-based or cell-based manufacturing. A flu shot can be designed and produced in weeks rather than months, a feature that matters when the circulating strain drifts mid-season. The commercial question is whether that advantage translates to market share in a roughly $7 billion global flu vaccine market dominated by Sanofi’s Fluzone franchise, GSK’s Fluarix, and CSL Seqirus’ Flucelvax, each of which holds multi-year contracts with pharmacy chains and health systems.

The split label reflects two distinct evidence packages. The standard approval for adults 50 to 64 rests on the full efficacy dataset. The accelerated approval for adults 65 and older comes with a post-marketing requirement for confirmatory data, a condition that could shape how the CDC’s Advisory Committee on Immunization Practices (ACIP) evaluates mFLUVISA for the 2026-27 flu season.

What to watch next: the ACIP recommendation. Even with an FDA approval, the CDC’s advisory committee decides whether mFLUVISA joins the annual flu vaccine roster on equal footing with established products. That vote, expected in the coming months, will determine whether Moderna gets a real commercial launch or a technical approval with no distribution channel.

The flu approval also strengthens the case for Moderna’s combination vaccine pipeline: flu-COVID and flu-RSV shots that would let the company compete on convenience rather than efficacy alone. Each mRNA approval that clears regulatory review makes the platform argument harder to dismiss. Moderna’s market cap stands at roughly $21 billion, and the stock has been range-bound near $57 as investors wait for revenue diversification to materialize.

What It Means for the Trade

The approval landing flat at $56.26 is the tell: the market had fully priced a 9-0 advisory committee vote, and an approval is only the start of the commercial question. An approval without distribution is a technicality — the real gate is the ACIP recommendation for the 2026-27 season, which decides whether mFLUVISA appears on order sheets next to Fluzone and Flucelvax or sits on the shelf as an oddity.

The split label complicates the launch. Standard approval for 50-64 is clean; accelerated approval for 65+ comes with a confirmatory post-marketing requirement, and ACIP has historically been conservative about preferentially recommending products on accelerated pathways for elderly populations. The 65+ segment is where flu vaccine volume and reimbursement concentrate, so the burden of the accelerated label lands on exactly the customers Moderna most needs.

The platform value is the real story. Spikevax’s COVID franchise is declining, and mFLUVISA is the first proof the mRNA platform can produce a second licensable commercial product. Flu-COVID and flu-RSV combinations would compete on convenience — one jab instead of two or three — and that is the credible path back to growth. But convenience plays need ACIP scheduling and procurement wins first, none of which exist yet.

Mechanism and Market Context

The Phase 3 is genuinely impressive as a dataset: roughly 73,000 participants across hemispheres, a 26.6% relative efficacy advantage over standard-dose comparators (95% CI 16.7% to 35.4%), with both noninferiority and superiority prespecified and met. By flu-vaccine trial standards, that is about as clean as the evidence gets — most flu efficacy debates grind on tiny single-season trials. The manufacturing argument is the structural differentiator: mRNA strain matching takes weeks versus the months egg-based production needs, which matters in drift seasons where the vaccine mismatch makes headlines.

The competitive set should not be underestimated. Sanofi’s Fluzone franchise and GSK’s high-dose offerings own the senior segment, Seqirus’s cell-based Flucelvax already markets faster strain-updating as its advantage, and pharmacy chains buy on price and reliability of supply. An entrant with a superiority claim but a first-year supply chain will not win share on data alone.

Risks and What Could Go Wrong

1. ACIP placement. Anything short of a routine recommendation — a shared clinical decision framework or category B placement — caps the launch at niche uptake.
2. Accelerated-approval drag in 65+. The confirmatory requirement gives ACIP a reason to wait, and gives competitors a talking point.
3. Pricing. mRNA cost of goods is higher than egg-based flu shots in a market that has always been margin-thin; underbidding on price to buy share would pressure the whole flu P&L.
4. Platform overhang. If the flu launch underwhelms, the combination-vaccine thesis loses its lead domino, and the $21 billion cap starts looking expensive against a declining COVID base.

Hold as a platform option, not a flu-launch story. The ACIP vote is the next real catalyst.